



## COLITIS

# Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor–induced colitis

Taylor M. Halsey<sup>1†</sup>, Anusha S. Thomas<sup>2†</sup>, Tomo Hayase<sup>3</sup>, Weijie Ma<sup>2,4</sup>, Hamzah Abu-Sbeih<sup>2,5</sup>, Baohua Sun<sup>6</sup>, Edwin Roger Parra<sup>6</sup>, Zhi-Dong Jiang<sup>7</sup>, Herbert L. DuPont<sup>7,8</sup>, Christopher Sanchez<sup>3</sup>, Rawan El-Himri<sup>3</sup>, Alexandria Brown<sup>3</sup>, Ivonne Flores<sup>3</sup>, Lauren McDaniel<sup>3</sup>, Miriam Ortega Turrubiates<sup>3</sup>, Matthew Hensel<sup>9</sup>, Dung Pham<sup>3</sup>, Stephanie S. Watowich<sup>10</sup>, Eiko Hayase<sup>3</sup>, Chia-Chi Chang<sup>3</sup>, Robert R. Jenq<sup>3,11‡</sup>, Yinghong Wang<sup>2\*‡</sup>

Immune checkpoint inhibitors (ICIs) target advanced malignancies with high efficacy but also predispose patients to immune-related adverse events like immune-mediated colitis (IMC). Given the association between gut bacteria with response to ICI therapy and subsequent IMC, fecal microbiota transplantation (FMT) represents a feasible way to manipulate microbial composition in patients, with a potential benefit for IMC. Here, we present a large case series of 12 patients with refractory IMC who underwent FMT from healthy donors as salvage therapy. All 12 patients had grade 3 or 4 ICI-related diarrhea or colitis that failed to respond to standard first-line (corticosteroids) and second-line immunosuppression (infliximab or vedolizumab). Ten patients (83%) achieved symptom improvement after FMT, and three patients (25%) required repeat FMT, two of whom had no subsequent response. At the end of the study, 92% achieved IMC clinical remission. 16S rRNA sequencing of patient stool samples revealed that compositional differences between FMT donors and patients with IMC before FMT were associated with a complete response after FMT. Comparison of pre- and post-FMT stool samples in patients with complete responses showed significant increases in alpha diversity and increases in the abundances of *Collinsella* and *Bifidobacterium*, which were depleted in FMT responders before FMT. Histologically evaluable complete response patients also had decreases in select immune cells, including CD8<sup>+</sup> T cells, in the colon after FMT when compared with non-complete response patients ( $n = 4$ ). This study validates FMT as an effective treatment strategy for IMC and gives insights into the microbial signatures that may play a critical role in FMT response.

## INTRODUCTION

Immune checkpoint inhibitor (ICI) therapies are oncologic treatment strategies that promote an antitumor response by impairing inhibitory T cell pathways. ICIs enhance immune-mediated responses to malignancies by bypassing checkpoints, including cytotoxic T lymphocyte–associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1). This checkpoint blockade enhances immunity by dampening normal protective immune tolerance mechanisms or

extending T cell effector responses and, thus, can sometimes trigger unwanted immune-related adverse events that may involve almost any organ system (1, 2).

The gastrointestinal (GI) tract is one of the organ systems that is most frequently affected by ICI-mediated immune-related adverse events. GI toxicities can vary in severity from mild disease to aggressive life-threatening clinical presentations that require immediate intervention. Milder cases of immune-mediated colitis (IMC) are managed supportively, whereas vigorous selective immunosuppression is implemented in aggressive disease in addition to withholding ICI therapy. Fecal microbiota transplantation (FMT) has also been reported to be beneficial in cases of IMC refractory to immunosuppression (3).

The gut microbiota comprises an assemblage of organisms, including resident bacteria, viruses, and fungi, and can vary with diet, lifestyle, and other environmental factors (4). Dysbiosis, or a change in the gut microbiota, including loss of beneficial microbes or expansion of pathogens, has been linked to cancer pathogenesis and impaired responses to cancer therapies (5–8). Certain gut bacterial signatures have been linked to ICI therapy responses, and others have been linked to the risk for developing IMC. Modulation of the gut microbiome in mice via FMT from patients with cancer results in substantial modulation of antitumor responses to ICI therapy (9–11). Similarly, specific bacterial taxa may modulate ICI-related toxicity: *Bacteroidetes* and *Bifidobacterium* have been

<sup>1</sup>Graduate School of Biomedical Sciences, Microbiology and Infectious Diseases, University of Texas MD Anderson Cancer Center UTHealth Houston, Houston, TX 77054, USA. <sup>2</sup>Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. <sup>3</sup>Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. <sup>4</sup>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province 430071, People's Republic of China. <sup>5</sup>Department of Internal Medicine, University of Missouri, Kansas City, MO 65211, USA. <sup>6</sup>Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. <sup>7</sup>Center for Infectious Diseases, School of Public Health, University of Texas, Houston, TX 77054, USA. <sup>8</sup>Kelsey Research Foundation, Houston, TX 77005, USA. <sup>9</sup>Middlebury College, Middlebury, VT 05753, USA. <sup>10</sup>Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. <sup>11</sup>Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.

\*Corresponding author. Email: ywang59@mdanderson.org

†These authors contributed equally to this work.

‡These authors contributed equally to this work.

reported to be associated with a lower risk of IMC, whereas *Faecalibacterium*, *Clostridia*, and *Escherichia* may pose an increased risk (12). Two early-phase studies in patients with melanoma for whom ICI therapy had previously failed recently demonstrated that FMT derived from patients who had responded to ICIs could result in cancer responses after additional ICI treatment (13, 14). Additional studies of microbiome manipulation with the goal of increasing the efficacy and reducing the toxicity of cancer therapies may result in the development of microbiome optimization strategies as an integral part of cancer treatment regimens.

Here, we document a case series of patients with IMC who were refractory to both first-line corticosteroids and standard second-line selective immunosuppression therapy (infliximab or vedolizumab) and who were subsequently treated with FMT as a third-line therapy. We describe the changes that were observed clinically, endoscopically, and histologically while also comparing microbial differences through analyses of gut microbiota composition.

## RESULTS

### Patient baseline characteristics

All 12 patients in our cohort were from the University of Texas MD Anderson Cancer Center; 100% were white and 75% were male, with a median age of 56 years [interquartile range (IQR) of 45 to 67 years] at the time of ICI initiation (Table 1). Half of the patients had received treatment with ICIs for genitourinary cancers (50%); the majority had stage IV disease (75%). With respect to ICI therapy, CTLA-4 blockade, PD-1 or PD-L1 blockade, and

combination therapy with CTLA-4 blockade and PD-1 or PD-L1 were used in one, six, and five patients, respectively.

### IMC characteristics and initial treatment

The median time from ICI initiation to the onset of adverse GI symptoms was 71 days (IQR of 14 to 586 days) (Table 2). All patients in our cohort had Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4 diarrhea; 50% also had CTCAE grade 3 or 4 colitis. On initial endoscopy at IMC onset, 50% had ulcerative inflammation. Ten patients (83%) were found to have chronic active inflammation on histologic examination. Each patient received but did not respond to systemic corticosteroids, which were given for a median duration of 68 days, followed by second-line selective immunosuppression with vedolizumab (median, 3 infusion doses) or infliximab (median, 2.5 infusion doses). Nearly all patients (92%) required hospitalization for IMC, with a median hospital stay of 15 days.

### FMT salvage therapy and clinical outcomes

FMT was given an average of 89 days after IMC symptom onset, and 83% ultimately achieved symptom improvement at a median duration of 14 days (IQR of 9 to 16 days) after treatment. Nearly half (42%) of the patients achieved both endoscopic and histologic remission at the last endoscopic follow-up. Of the 12 patients in our cohort, 3 received additional FMT for partial responses, and 2 of 3 achieved complete response (CR). There were no FMT-related complications at 7 and 30 days in our entire sample. Four patients required additional immunosuppressant treatment for IMC after FMT. At the end of the study period, 92% had achieved clinical remission of their IMC. With respect to cancer progression, three patients (25%) had experienced cancer progression by the time of FMT. Four patients (33%) underwent non-ICI cancer therapy after FMT, and three later succumbed to their underlying malignancy. Stool samples were collected from 9 of 12 patients within 24 hours before FMT (pre-FMT; day 0). Each patient also provided a post-FMT stool sample ( $n = 12$ ; range: day 10 to 120; median: day 28). Aliquots of the donor FMT product ( $n = 12$ ) were also stored for independent evaluation. Three patients received a second therapeutic FMT after the first FMT did not successfully resolve their IMC symptoms. Information regarding available samples collected at specific time points from individual patients is provided in table S1.

### Baseline patient microbial composition predicts IMC FMT response


We compared the microbiome composition of pre-FMT stool samples using 16S ribosomal RNA (rRNA) sequencing from patients with CR with those from patients with non-CR and healthy controls, the latter represented by FMT donors. No significant differences ( $P \geq 0.5$ ) in microbial alpha diversity were seen between patients with CR and non-CR or FMT donors (including second FMTs for two patients with non-CR), as measured by the inverse Simpson's index (Fig. 1A). We also examined stool samples from controls with pre-FMT samples from patients with CR and non-CR using principal coordinates analysis (PCoA) to visualize beta diversities of baseline samples (Fig. 1B). Donor stools were distinct from the stools of patients with CR [permutational multivariate analysis of variance (PERMANOVA),  $P = 0.01$ ], whereas differences between donor and patient with non-CR stool samples were not

**Table 1. Patients' baseline characteristics ( $n = 12$ ).**  
IQR, interquartile range.

Characteristic	Data ( $n = 12$ )
Median age at time of ICI initiation, years (IQR)	56 (45–67)
Male sex, no. (%)	9 (75)
White race, no. (%)	12 (100)
Cancer type, no. (%)	
Genitourinary	6 (50)
Melanoma	3 (25)
Gastrointestinal	1 (8)
Head and neck	1 (8)
Hematological cancer	1 (8)
Cancer stage, no. (%)	
Stages I–II	2 (17)
Stage IV	10 (83)
Checkpoint inhibitor type, no. (%)	
Anti-CTLA-4	1 (8)
Anti-PD(L)1	6 (50)
Combination	5 (42)
Median number of ICI infusions before IMC, no. (IQR)	9 (1–25)
Immunotherapy stopped because of IMC, no. (%)	12 (100)
Median follow-up duration from IMC, months (IQR)	22 (3–44)

**Table 2. Characteristics and outcome of IMC (n = 12).** Six patients received both infliximab and vedolizumab before FMT. All three patients who died were in remission or had responded. FMT, fecal microbiota transplantation.

Characteristic	Data (n = 12)	CR (n = 7)	Non-CR (n = 5)
Median time from ICI to IMC, days	71 (14–586)	69 (14–189)	171 (47–586)
Highest grade of diarrhea, no. (%)			
3 or 4	12 (100)	7 (100)	5 (100)
Highest grade of colitis, no. (%)			
1 or 2	6 (50)	4 (57.1)	2 (40)
3 or 4	6 (50)	3 (42.9)	3 (60)
Initial endoscopic findings, no. (%)			
Ulcers	6 (50)	4 (57.1)	2 (40)
Non-ulcer inflammation	3 (25)	2 (28.6)	1 (20)
Normal	3 (25)	1 (14.3)	2 (40)
Initial histology findings, no. (%)			
Active inflammation	2 (16.7)	1 (14.3)	1 (20)
Chronic active inflammation	9 (75)	6 (85.7)	3 (60)
Normal	1 (8.3)	0	1 (20)
Hospitalizations, no. (%)	11 (92)	7 (100)	4 (80)
Median duration of hospitalization, days	15 (5–63)	12 (5–31)	7 (0–30)
Treatment of GI adverse events, no. (%)			
Steroid	12 (100)	7 (100)	5 (100)
Infliximab/vedolizumab added	12 (100)	7 (100)	5 (100)
Median duration of steroid treatment, days	68 (46–93)	70 (46–117)	81 (36–130)
Median number of infliximab infusions before FMT, no.	1 (0–4)	0 (0–4)	2 (0–4)
Median number of vedolizumab infusions before FMT, no.	3 (2–4)	3 (2–4)	3 (2–4)
FMT characteristic and outcome			
Median time from initial IMC to FMT, days	89 (58–386)	100 (71–305)	78 (58–386)
Median duration of colitis or diarrhea symptoms, days	57 (1–235)	125 (1–235)	31 (1–72)
Symptom improvement after FMT, no. (%)	10 (83)	7 (100)	3 (60)
Median time from FMT to symptom improvement, days	14 (9–16)	10 (0–20)	14 (5–14)
FMT-related complications within 7 days, no. (%)	0	0	0
FMT-related complications within 30 days, no. (%)	0	0	0
Cancer status at the time of FMT, no. (%)			
Remission	3 (25)	1 (14.3)	2 (40)
Stable disease	7 (58.3)	5 (71.4)	2 (40)
Progression	2 (16.7)	1 (14.3)	1 (20)
Required selective immunosuppressants for recurrent or refractory colitis after FMT, no. (%)	4 (33.3)	2 (28.5)	2 (40)
Resumed cancer treatment after FMT, no. (%)	4 (33)	2 (28.5)	2 (40)
Endoscopic remission achieved by last follow-up, no. (%)	5 (42)	5 (71.4)	0
Histology remission achieved by last follow-up, no. (%)	3 (25)	3 (42.9)	0
Colitis status at the end of the study period			
Clinical remission, no. (%)	11 (92)	6 (85.7)	5 (100)
Persistent symptoms, no. (%)	1 (8)	1 (14.3)	0
Cancer status at last follow-up, no. (%)			
Remission	3 (25)	1 (14.3)	2 (40)
Stable disease	3 (25)	1 (14.3)	2 (40)
Progression	6 (50)	5 (71.4%)	1 (20)
Mortality, no. (%)	3 (25)	2 (28.5)	1 (20)



**Fig. 1. Comparisons of alpha and beta diversity of baseline pre-FMT samples from patients with IMC treated with FMT versus healthy individuals.** (A) Alpha diversity by inverse Simpson index on samples from healthy individuals (FMT donors), pre-FMT samples from patients with complete response (CR), and pre-FMT samples from patients with non-complete response (non-CR) compared using Mann-Whitney test. (B) Principal coordinates analysis (PCoA) of FMT donors ( $n = 11$ ) and patients with CR ( $n = 6$ ) and non-CR ( $n = 3$ ) samples; significance was assessed with PERMANOVA statistical testing. Axis percentage labels represent variance explained. (C) Differentially abundant bacterial genera in samples collected pre-FMT from patients with CR compared with non-CR using DESeq2 with adjustment for multiple comparisons using the Benjamini-Hochberg method. (D) Differentially abundant bacterial genera in samples collected pre-FMT in patients with CR compared with samples from healthy FMT donors, analyzed as in (C). ns, not significant.

statistically significant ( $P = 0.4$ ), nor were there significant differences between patients with CR and non-CR ( $P = 0.8$ ; fig. S1). Differential abundance analyses revealed that two bacterial genera, *Bifidobacterium* and *Collinsella*, were depleted in patients with CR at baseline compared with patients with non-CR (Fig. 1C) and were also depleted in patients with CR compared with FMT donors (Fig. 1D). In contrast, several other genera were enriched in patients with CR (Fig. 1C). Overall, our analyses of pre-FMT microbial compositions from patients with IMC revealed that CR was more dissimilar to FMT donors than patients with non-CR, and the stool samples of patients with CR were characterized by low abundances of *Bifidobacterium* and *Collinsella*.


Next, we evaluated the effects of FMT on the fecal microbiota composition of individual patients with IMC. We evaluated beta diversity of pre-FMT, post-FMT, and donor samples for four patients with CR and three patients with non-CR for whom post-FMT samples collected on day  $30 \pm 20$  after FMT were available (Fig. 2A). Whereas all four patients with CR became more similar to their FMT donor when comparing pre- and post-FMT samples,

two of three patients with non-CR actually became less similar to their FMT donor (Fig. 2, B and C).

### Select bacterial taxa are associated with IMC FMT response

Our results suggested that success of FMT for treating IMC may depend to an extent on whether the FMT procedure results in a microbiota composition that is more similar to that of the donor. Consistent with this, we found that in patients with CR, the FMT procedure consistently increased alpha diversity, whereas two of three patients with non-CR actually experienced reductions in alpha diversity (Fig. 3A). The compositions of stool samples collected at each time point for all individual patients are presented in fig. S2.

To identify specific bacterial taxa that could be mediating a benefit in patients with CR, we identified differentially abundant genera after FMT in these patients using a paired analysis. We found that *Collinsella*, *Bifidobacterium*, Family XIII AD3011 group, and *Coprococcus* were all enriched in patients with CR after FMT, whereas *Tyzerella* was reduced (Fig. 3, B and C). In




**Fig. 2. Changes in beta diversity predict IMC response to FMT.** (A) PCoA of samples from patients with IMC and either a CR (blue) or non-CR (orange). Pre-FMT (square), post-FMT (day 30  $\pm$  20; circle), and corresponding FMT donor sample (star) for each patient are indicated in the figure. Solid lines indicate linked pre- and post-FMT samples, whereas dashed lines indicate linked post-FMT and FMT donor samples. Axis percentage labels represent variance explained. (B) Beta diversity distances were quantified using weighted UniFrac values comparing pre- and post-FMT samples against FMT donor samples in patients with IMC and either CR or non-CR. Data are shown using both bar and paired dot plots. Comparisons were analyzed using Mann-Whitney test.


this work, we had already found that pre-FMT samples from patients with CR were depleted in *Collinsella* and *Bifidobacterium*. Together, these results suggest that reduced *Collinsella* and *Bifidobacterium* could potentially identify FMT candidates who are then more likely to experience increases in these bacterial subsets from the FMT procedure. We further validated these results using real-time quantitative polymerase chain reaction (qPCR; fig. S4); *Bifidobacterium* was enriched after FMT in patients with CR, whereas changes in *Collinsella* abundance were more heterogeneous and could not be recapitulated using real-time qPCR. To gain potential insights into the taxonomic resolution of these associations beyond the genus level, we performed whole-DNA shotgun sequencing of a subset of samples that had sufficient biomass to be evaluated. We found that most *Bifidobacteria* in samples from this

cohort belonged to *Bifidobacterium dentium*, and most *Collinsella* belonged to *Collinsella intestinalis* (fig. S3) with the exception of patient 1, who experienced a CR and harbored *Bifidobacterium longum*, *Bifidobacterium pseudocatenulatum*, and *Collinsella aerofaciens* after FMT.

We next asked whether any clinical features of patients were associated with the taxa of interest identified by 16S rRNA sequencing at baseline before undergoing FMT. We examined correlations between taxa abundances and clinical features that were continuous or categorical. Relative abundances of *Collinsella* and *Coprococcus*, which increased after FMT in all patients with CR, were inversely correlated with the duration of colitis and diarrhea symptoms (Fig. 4A). Most clinical characteristics that were not related to IMC symptomatology (such as age, sex, ICI type, and cancer



**Fig. 3. Increases in alpha diversity and specific bacterial taxa are associated with FMT response.** (A) Comparison of alpha diversity by inverse Simpson index pre-FMT (baseline) and post-FMT (day 30 ± 20) in CR and non-CR patients with IMC using paired Wilcoxon test. (B) Volcano plot of differentially abundant bacterial genera comparing pre-FMT and post-FMT samples from patients achieving a CR using paired Wilcoxon test with adjustments for multiple comparisons (Benjamini-Hochberg method). (C) Relative abundance of significantly ( $P < 0.05$ ) changed bacterial genera identified in (B) quantified in paired samples for patients with CR and non-CR.



**Fig. 4. Associations of select taxa with pre-FMT clinical features of patients with IMC. (A)** Spearman’s rank correlation of clinical variables with bacterial taxa before FMT. **(B)** Binary clinical associations using DESeq2. Log<sub>2</sub>fold change represents effect size, and directionality is indicated next to each clinical feature (red/blue). Previously identified taxa of interest (Fig. 3) are present at the bottom of each heatmap on the basis of response to FMT therapy (CR, green; non-CR, orange). All available clinical features were considered (see Tables 1 and 2). Significance was assessed using calculated values normalized to each sample mean, and data were scaled for visualization using heatmaps generated in R.

stage) did not show significant associations with the bacterial taxa of interest (Fig. 4B). Collectively, these data suggest that some clinical features may explain baseline differences in the abundances of taxa associated with FMT response.


### Changes to the gut immune environment after administration of FMT

We asked whether the effects of FMT therapy were associated with changes in immune infiltrating populations or epithelial proliferation in the colon. We performed multiplex immunofluorescence (IF) on formalin-fixed paraffin-embedded (FFPE) colon tissue samples collected from patients with IMC in the cohort who had paired samples collected before and after FMT, including two patients with CR and two patients with non-CR. Quantification of IF images showed that total (CD3<sup>+</sup>) T cells and, more specifically, CD8<sup>+</sup> T cells decreased in both patients with CR after FMT but not in both patients with non-CR (Fig. 5, A and B). Representative IF images from select patients are shown in Fig. 5C. These data suggest that CR of IMC by FMT therapy might be mediated by loss of total lymphocytes (CD3<sup>+</sup>) and cytotoxic T cells (CD3<sup>+</sup> CD8<sup>+</sup>). Additional markers, including FoxP3<sup>+</sup> regulatory T cells (CD4<sup>+</sup> FoxP3<sup>+</sup>), B cells (CD20<sup>+</sup>), natural killer cells (CD56<sup>+</sup>), epithelial cells (CK<sup>+</sup>), and proliferating cells (Ki67<sup>+</sup>), showed no clear patterns (fig. S5).

### DISCUSSION

ICI has revolutionized the management, outcome, and overall survival of patients with many types of malignancies. However, IMC can cause morbidities with a wide range of severity (15–17). The mainstay of medical treatments for moderate to severe IMC is limited to immunosuppressive agents such as corticosteroids, infliximab, and orvedolizumab, as well as reports of success with administering interleukin-12/23 (IL-12/23) blockade (18), IL-6 receptor antagonist therapy (19), and Janus kinase inhibition (20) for refractory disease cases. Given the increasing recognition that patients with longer disease courses of colitis disease may have improved cancer response rates (21), therapeutic options that can avoid abrogating beneficial effects of ICI, such as FMT, are needed. In this case series, which is an extension of our previous two-patient case series (3), we demonstrated a high clinical response rate of 83% to FMT in treating refractory IMC, with only mild adverse events. In addition, we also described microbiome features associated with favorable responses to FMT.

Gut dysbiosis, or an imbalance in the normal gut flora, may alter host responses, promote a chronic inflammatory state, and affect a variety of cancer outcomes, including cancer development, progression, and response to cancer therapeutic agents (22–25). Differential gut microbial signatures have been identified among ICI therapy responders versus nonresponders, as well as among those with a predisposition for developing IMC (12, 26, 27). Modulation of the



**Fig. 5. Immune infiltrate changes in FMT-treated patients with IMC.** Multiplex immunofluorescence quantification of (A) total CD3<sup>+</sup> and (B) CD3<sup>+</sup> CD8<sup>+</sup> T cells. Total area of colonic epithelia and stromata of patients with IMC was used to quantify changes in immune cells. Individual patients are depicted using shapes. (C) Representative immunofluorescent images depicting CD3<sup>+</sup> and 4',6-diamidino-2-phenylindole (DAPI), CD8<sup>+</sup> and DAPI and merged for patients with IMC treated with FMT. Scale bars, 50  $\mu$ m. *P* values are not reported because of small sample size.



gut microbiome in gnotobiotic mice via FMT from patients with cancer alters antitumor immunity and response to ICIs. Prospective clinical trials have also raised the possibility that microbiome modulation improves cancer responses among patients with melanoma who previously did not respond to ICI therapy after receiving FMT from patients with melanoma who did respond (10, 11, 13). In addition, microbe-based adjuvants for enhancing ICI therapy are emerging as suitable strategies for augmentation of select cancers (28). Relatedly, it has been hypothesized that targeting specific gut bacterial taxa may abrogate ICI-related toxicity (12, 29, 30). FMT has been speculated to be effective in patients with ICI-induced enterocolitis that is refractory to standard-of-care immunosuppressive therapy, which is further supported by the current study with a larger sample analysis. A future prospective clinical trial (<https://clinicaltrials.gov/ct2/show/NCT03819296>) will provide more evidence in measuring the efficacy and safety of FMT as a therapeutic.

FMT for the treatment of refractory IMC represents an approach to a common and detrimental side effect of ICI therapy. We presented data that suggest that the microbiome of patients with IMC can be manipulated by FMT and that these changes in the composition of the intestinal microbiome may confer a health benefit to recipients. Paired analyses of patient stool samples showed a substantial increase in alpha diversity in responders. This result is consistent with those of numerous published reports that suggest that greater microbial diversity is typically associated with better overall health and that patients with a less-diverse gut microbiome often have related inflammatory conditions (31). In addition, we observed a substantial difference in the beta diversity of donor stool and pre-FMT stool in patients with CR, indicating that patients who ultimately responded to FMT had greater dysbiosis at baseline. This association could be due to the greater ability of FMT-derived bacteria to engraft in dysbiotic hosts. An alternative, nonexclusive explanation is that, in a subset of patients with refractory IMC, microbiome dysbiosis drives colitis pathophysiology, whereas in other patients, the microbiome is not a significant contributor. In addition, IMC may be a driver of host dysbiosis because host genetics also influence microbial composition (32–34). Further studies identifying whether the hosts have genetic predispositions to inflammation may also inform whether a patient would benefit from FMT as a treatment for IMC.

Two genera of bacteria, *Bifidobacterium* and *Collinsella*, were depleted in patients with CR before FMT and then increased substantially after a successful response. Members of these genera belong to the phylum Actinobacteria and are anaerobic, Gram-positive, nonmotile, nonsporulating rods that commonly reside in the GI tracts of humans and other mammals (35). Many species of the genus *Bifidobacterium* (for example, *B. longum*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, and *Bifidobacterium infantalis*) are currently in use as probiotic supplements that have been reported to alleviate GI inflammation (36, 37). In preclinical models, introducing *Bifidobacterium* spp. led to improved tumor responses to anti-PD-1 or oxaliplatin therapy and mitigated anti-CTLA-4-induced colitis (30, 38). These effects seem to be at least partially modulated through the increased presence of regulatory T cells or secretion of the anti-inflammatory cytokine IL-10 (39). Note that we did not see changes in regulatory T cells in our immune cell evaluation of colon tissue between patients with CR and non-CR.

Less is known about *Collinsella* in the context of IMC. Some studies have found that *Collinsella* bacteria are associated with

inflammatory states (40, 41). However, *C. aerofaciens* has been previously shown to be more abundant in patients with metastatic melanoma who respond favorably to anti-PD-1 therapy; the same study found numerous species of the *Bifidobacterium* genus that were also associated with anti-PD-1 efficacy in both patients and mice (11). In patients with ulcerative colitis who had been treated with FMT, Bifidobacteriaceae and Coriobacteriaceae (which contain *Bifidobacterium* and *Collinsella*, respectively) showed increased abundance in patients who achieved clinical remission (40). Our results suggest that *Bifidobacterium* and *Collinsella* species may protect some patients against developing IMC and that proliferating these bacteria can protect against or reduce the severity of IMC. Previous studies demonstrate that *Collinsella* has been shown to alter gut physiology, induce expression of IL-17 network cytokines, and affect T cell-mediated responses (42, 43). We also identified additional potentially beneficial bacteria, including *Coprococcus* and Family XIII AD3011 group, which were found to be decreased in patients with inflammatory bowel disease, suggesting that their recovery may reduce gut inflammation (44, 45). Conversely, *Tyzerella*, which had lower abundance in patients with CR after FMT, was recently found to be enriched in the ileal mucosal biopsies of patients with Crohn's disease compared with those of healthy controls (46). Further research is still needed to determine how these taxa contribute to IMC disease phenotypes.

IMC is caused in large part by stimulation of the host immune system by ICI treatment. Gut commensal modulation of the immune system has been well described (25, 47–52), but more studies are needed in the context of IMC. Our analyses of colon biopsies from patients with IMC showed a marked decrease in both total lymphocytes and CD8<sup>+</sup> T cells in complete responders after FMT, suggesting FMT-mediated reduced inflammation in complete responders. This also led to changes in the ratios of regulatory T cells to cytotoxic T cells, which may also have played a role in disease mediation. Multiplex IF profiling of additional immune cells and epithelial markers revealed trends that may lead to FMT-mediated mechanisms of action in IMC treatments. Additional studies are necessary to confirm results and explore pathways of interest within these cell subtypes.

Our study is limited by its retrospective nature, small sample size, and lack of a control arm to appropriately measure the impact of FMT on colitis outcomes. However, FMT is not yet established or recommended as a standard treatment of choice for refractory IMC. This is, however, offered as a compassionate therapy to patients at our institution. In addition, the gut microbiome is highly sensitive to a variety of factors, including but not limited to antibiotic use; medications; diet; smoking; and demographic, oncologic, immunologic, and geographic factors, all of which are beyond the scope of our case series. We used real-time qPCR to validate findings from 16S rRNA sequencing and found that we could recapitulate the results for *Bifidobacterium*; *Collinsella* samples proved to be more heterogeneous, and low initial abundance in IMC patient samples could have contributed to poor amplification efficiency. Note that correlation analyses showed discrepancies between the relative abundance from 16S rRNA sequencing and fold change from real-time qPCR. It could be that *Collinsella* qPCR primers do not well-amplify all species of *Collinsella* or could alternatively be amplifying non-*Collinsella* species. Corroborating this possibility, we found that, for *Bifidobacterium*, abundances quantified by 16S and qPCR generally showed reasonable correlations ( $R =$

0.81), whereas abundances for *Collinsella* were not as well-correlated ( $R = 0.54$ ).

This study demonstrated the utility of gut microbial manipulation via FMT in the management of ICI toxicity in a series of 12 patients with advanced cancer. Our study showed that FMT was generally well-tolerated in these patients. Furthermore, we provide preliminary data to suggest that initial gut dysbiosis and increased alpha diversity after FMT may be favorable in predicting FMT-related efficacy for IMC management. These observations may serve as a foundation to inform the design of larger prospective placebo-controlled studies to evaluate the therapeutic efficacy of targeting the gut microbiome to avoid or treat ICI gut toxicities and ensure continuance of cancer care.

In summary, manipulation of the gut microbiota through FMT represents a promising approach to the treatment of IMC in patients who are otherwise refractory to first- and second-line standard immunosuppressive treatment. In addition, our studies identified a potential role for FMT-mediated changes in select immune cells that mediate IMC severity. Larger prospective studies will be needed to fully characterize the efficacy and safety of this strategy and to better identify microbiome parameters that can prognosticate IMC severity and FMT response. In our case series, we found minimal adverse events attributable to FMT. We expect that FMT will become a useful approach to treat patients with IMC at earlier stages of presentation, as an addition or alternative to standard treatments, which could, in turn, be guided by insights from this study into unique microbial signatures that may play a role in the therapeutic IMC response to FMT.

## MATERIALS AND METHODS

### Study design

We determined the impact of FMT from healthy donors on the outcome of patients with refractory IMC. We identified 12 patients at the University of Texas MD Anderson Cancer Center who met the following inclusion criteria: (i) adult patients with cancer aged 18 years and older, (ii) diagnosis of IMC with diarrhea and/or colitis-related symptoms (such as bleeding, pain, and mucus in the stool), (iii) lack of response to or recurrence with  $\geq$  grade 2 GI symptoms after first- and second-line standard therapy for IMC, and (iv) absence of active infection and no clinical indication for antibiotics at the time of FMT. Patients with concurrent GI infection were excluded from this case series. First line of therapy refers to weight-based systemic corticosteroids (1 to 2 mg/kg) with a taper course. Second line of therapy refers to biologics vedolizumab and/or infliximab. FMT was performed under individual compassionate Investigational New Drug (IND) applications that had been approved by the Institutional Review Board (IRB) and authorized by the U.S. Food and Drug Administration (FDA) between June 2017 and April 2020. Data follow-up of this study ended on December 2021.

### Clinical and oncological data

Baseline demographic data (including age, sex, and race), oncology variables (cancer type and stage and ICI therapy type), and IMC characteristics (including severity grade of diarrhea and colitis, medical treatment received, and outcomes) were extracted from institutional electronic medical records and pharmacy databases. IMC severity at different time points was measured using CTCAE version

5.0. The use of antibiotics after FMT was also collected as a potential factor affecting microbiome composition. Medical treatments of IMC were categorized as non-immunosuppressive or immunosuppressive. Treatment response was defined as clinical improvement of symptoms of IMC with a lower CTCAE grade or remission to CTCAE grade 1 or lower until the last follow-up. Recurrence refers to onset of active clinical symptoms (CTCAE) of IMC after the initial response or remission after medical treatment. Refractory IMC refers to the persistent colitis symptoms despite abovementioned therapy for a minimum duration of 2 weeks. These patients were routinely taken off immunosuppressants after FMT treatment. The immunosuppressant regimen was resumed if FMT was ineffective. Cancer status at the IMC onset and last follow-up after FMT was classified as stable, remission, or disease progression. Patients' vital status and survival at the last follow-up were also recorded.

### Endoscopic and histological evaluation

Data on symptoms and endoscopic evaluation were collected before and after FMT, as available usually starting within 1 week before and for a 2-month window after treatment. Endoscopic findings included mucosal ulcerations, non-ulcer inflammation (erythema, exudate, loss of normal vascularity, and atrophy), or a normal appearance. Histological patterns were graded as acute colitis, chronic active colitis, microscopic colitis, or normal. Endoscopic and histological classification criteria have been previously described (3). Endoscopic and histological remissions were assessed as secondary outcomes, which were defined as endoscopic resolution of ulceration or non-ulcer inflammation and resolution of active histological inflammation, respectively.

### Fecal microbiota transplantation

FMT treatment was performed following an institutional protocol. Once an eligible patient had been identified, an individual compassionate Investigational New Drug application was requested from the IRB and approved by the FDA before treatment. Patients were consented to an individual IND and IRB protocol on a separate occasion at the time of indication. Healthy donor stool samples were provided by the stool bank of the University of Texas School of Public Health (H.D.'s laboratory). Donors completed screening questionnaires and underwent laboratory testing, as required by FDA regulations. FMT was performed via colonoscopy after routine colon cleansing with polyethylene glycol, with delivery of 50 g of donor stool in liquid form to the right colon. Patients were observed for 1 hour in the endoscopy unit before being discharged. Clinical symptoms and side effects were monitored daily for the first 7 days and again at 30 days. Response after FMT and duration of response were recorded. CR to FMT was defined as CTCAE grade  $\leq 1$  of GI symptoms within 30 days after FMT. A partial response to FMT was defined as a reduction in the CTCAE grade of GI symptoms that did not meet the criteria of CR after first FMT or recurrent symptoms within 6 weeks that necessitated a second FMT. Nonresponders were those who had persistent, unchanged symptoms within 30 days despite FMT. Extra aliquots of donor stool samples, as well as patient stool samples collected at time points before and after FMT, were stored for subsequent analysis.

### DNA extraction and 16S rRNA sequencing for microbiome analyses

Genomic DNA was isolated from stool samples using the commercially available QIAamp DNA stool mini kit (QIAGEN) according to the manufacturer's protocol, modified to include an additional lysis step via bead beating. One 3.2-mm steel bead, 150 mg of zirconium beads, and lysis buffer were added into each tube containing pre-weighed stool samples for DNA isolation. Stool samples underwent bead beating for 8 min (two repetitions of 4 min) at 3800 rpm. The V4 region of the 16S rRNA gene was amplified by PCR from 100 ng of each extracted and purified genomic DNA using 515 forward and 806 reverse primer pairs. The QIAquick gel extraction kit (QIAGEN) was used to purify the amplicon pool and sequenced on the Illumina MiSeq sequencer platform using a 2 × 250–base pair (bp) paired-end protocol. Paired-end reads were demultiplexed using QIIME2 (53), merged and de-replicated using VSEARCH (54), denoised with UNOISE 3 (55), and classified using mothur (56) with the Silva database version 138 (57). Alpha diversity and weighted UniFrac beta diversity (58) were quantified using QIIME2.

### Whole-genome shotgun sequencing

Genomic DNA was extracted from stool samples taken from patients with IMC in the same manner as 16S rRNA sequencing (see above). Libraries for shotgun sequencing preparation were constructed using the Illumina DNA Prep Kit (Illumina) according to the manufacturer's protocol. The final libraries were loaded into the NovaSeq 6000 platform (Illumina) and sequenced 2 × 150-bp paired-end read, resulting in ~5 Gb per sample. NovaSeq raw reads were filtered by their phred quality score of less than or equal to 15 by VSEARCH. Bacterial taxonomic alignment and pathway analyses were done by HUMAnN 3.0 (59).

### Real-time qPCR

The remaining genomic DNA after 16S rRNA sequencing was aliquoted and normalized to 10 ng with ultrapure, nuclease-free water for use in real-time qPCR. qPCR was performed as previously described (60). Briefly, real-time PCR was carried out in 96-well optical plates on the QuantStudio Flex 6 RT-PCR (Thermo Fisher Scientific) and KAPA SYBR FAST 2X Master Mix (Applied Biosystems). Primers used in this assay have been previously described elsewhere: *Bifidobacterium* (61) and *Collinsella* (62). The PCR conditions included one initial denaturing step of 10 min at 95°C and 35 cycles of 95°C for 15 s and 55°C (*Bifidobacterium*) and 60°C (*Collinsella*) for 1 min. Melting curve analysis was performed after amplification to improve amplification specificity. The 16S rRNA gene sequences were amplified from the total fecal DNA using the primers 926F (5'-AAACTCAAAGGAATTGACGG-3') and 1062R (5'-CTCACRRCACGAGCTGAC-3') as endogenous controls.

### Multiplex IF

Multiplex IF staining was performed using similar methods and reagents that have been previously described (63). Briefly, 4-µm-thick FFPE tissue sections were automated using the staining system Leica BOND-RX (Leica Microsystems) against the following: cytokeratin (dilution 1:50; clone AE1/AE3, Dako), CD3 [dilution 1:100; clone D7A6E (AM), Cell Signaling Technology], CD8 (dilution 1:25; clone C8/144B, Thermo Fisher Scientific), CD4 (dilution 1:200; clone EPR6855, Abcam), CD56 (dilution 1:25; clone 123C3, Dako), FOXP3 (dilution 1:100; clone D2W8E, Cell Signaling

Technology), CD20 (dilution 1:50; clone L26, Dako), and Ki67 (dilution 1:100; clone MIB-1, Dako). All the markers were stained in sequence using their respective fluorophore in the Opal 7 kit (catalog no. NEL797001KT, Akoya Biosciences) and the TSA fluorophore Opal Polaris 480 (no. FP1500001KT, Akoya Biosciences). Stained slides were scanned using the multispectral microscope, Vectra Polaris 3.0.3 imaging system (Akoya Biosciences), under fluorescence and low magnification at ×10. After scanning, a pathologist selected representative regions of interest (ROIs; each ROI is 0.63 mm<sup>2</sup>) per sample using the phenochart 1.0.9 viewer (Akoya Biosciences) (64). ROIs were analyzed using the InForm 2.8.2 image analysis software (Akoya Biosciences). Marker colocalization was used to identify different cellular phenotypes and was quantified as number of cells square millimeter in mucosa and in the submucosa compartment. Data were consolidated using the R studio 3.5.3 (Phenopter 0.2.2 packet, Akoya Biosciences).

### Statistical analysis

For 16S rRNA sequencing differential abundance analyses, bacterial genera were ranked by median abundance and variance and analyzed using Mann-Whitney test; the highest 20 features were analyzed using DESeq2 (65) and corrected for the false discovery rate (FDR) using the Benjamini-Hochberg method (66). Paired abundance testing was performed using the Wilcoxon test after logit transformation. The details of our computational analysis pipeline have been described previously (3). Spearman correlation analysis was performed between continuous clinical parameters and relative abundances of microbiome as well as for comparisons between relative abundance data generated from 16S rRNA sequencing, whole-genome shotgun sequencing, and real-time qPCR. The differences between discrete values in clinical parameters and microbial relative abundances were analyzed using DESeq2. *P* values were adjusted using FDR. Differences were considered significant if *P* < 0.05. Data were visualized using volcano plots, correlation analyses, and heatmaps created in R Studio 3.5.3. Any additional analyses, including Student's *t* tests and tests for normality between groups, were performed using GraphPad Prism version 8.0 (GraphPad Software).

### Supplementary Materials

#### This PDF file includes:

Figs. S1 to S5  
Table S1

#### Other Supplementary Material for this manuscript includes the following:

Data file S1  
MDAR Reproducibility Checklist

[View/request a protocol for this paper from Bio-protocol.](#)

### REFERENCES AND NOTES

1. D. B. Johnson, R. J. Sullivan, P. A. Ott, M. S. Carlino, N. I. Khushalani, F. Ye, A. Guminski, I. Puzanov, D. P. Lawrence, E. I. Buchbinder, T. Mudigonda, K. Spencer, C. Bender, J. Lee, H. L. Kaufman, A. M. Menzies, J. C. Hassel, J. M. Mehnert, J. A. Sosman, G. V. Long, J. I. Clark, Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. *JAMA Oncol.* **2**, 234–240 (2016).
2. C. Ramamurthy, J. L. Godwin, H. Borghaei, Immune checkpoint inhibitor therapy: What line of therapy and how to choose? *Curr. Treat. Options Oncol.* **18**, 33 (2017).

3. Y. Wang, D. H. Wiesnoski, B. A. Helmink, V. Gopalakrishnan, K. Choi, H. L. DuPont, Z. D. Jiang, H. Abu-Sbeih, C. A. Sanchez, C. C. Chang, E. R. Parra, A. Francisco-Cruz, G. S. Raju, J. R. Strohlein, M. T. Campbell, J. Gao, S. K. Subudhi, D. M. Maru, J. M. Blando, A. J. Lazar, J. P. Allison, P. Sharma, M. T. Tetzlaff, J. A. Wargo, R. R. Jenq, Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. *Nat. Med.* **24**, 1804–1808 (2018).
4. D. A. Byrd, J. Chen, E. Vogtmann, A. Hullings, S. J. Song, A. Amir, M. G. Kibriya, H. Ahsan, Y. Chen, H. Nelson, R. Knight, J. Shi, N. Chia, R. Sinha, Reproducibility, stability, and accuracy of microbial profiles by fecal sample collection method in three distinct populations. *PLOS ONE* **14**, e0224757 (2019).
5. H. Abu-Sbeih, L. N. Herrera, T. Tang, M. Altan, A. M. P. Chافتari, P. C. Okhuysen, R. R. Jenq, Y. Wang, Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. *J. Immunother. Cancer* **7**, 242 (2019).
6. A. Elkrif, L. El Raichani, C. Richard, M. Messaoudene, W. Belkaid, J. Malo, K. Belanger, W. Miller, R. Jamal, N. Letarte, P. Wong, B. Routy, Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. *Oncoimmunology* **8**, e1568812 (2019).
7. J. R. Galloway-Peña, R. R. Jenq, S. A. Shelburne, Can consideration of the microbiome improve antimicrobial utilization and treatment outcomes in the oncology patient? *Clin. Cancer Res.* **23**, 3263–3268 (2017).
8. J. E. Martinez, D. D. Kahana, S. Ghuman, H. P. Wilson, J. Wilson, S. C. J. Kim, V. Lagisshetty, J. P. Jacobs, A. P. Sinha-Hikim, T. C. Friedman, Unhealthy lifestyle and gut dysbiosis: A better understanding of the effects of poor diet and nicotine on the intestinal microbiome. *Front. Endocrinol. (Lausanne)* **12**, 667066 (2021).
9. M. Vézizou, J. M. Pitt, R. Daillère, P. Lepage, N. Waldschmitt, C. Flament, S. Rusakiewicz, B. Routy, M. P. Roberti, C. P. M. Duong, V. Poirier-Colame, A. Roux, S. Becharef, S. Formenti, E. Golden, S. Cording, G. Eberl, A. Schlitzer, F. Ginhoux, S. Mani, T. Yamazaki, N. Jacquolot, D. P. Enot, M. Bérard, J. Nigou, P. Opolon, A. Eggermont, P.-L. Woerther, E. Chachaty, N. Chaput, C. Robert, C. Mateus, G. Kroemer, D. Raoult, I. G. Boneca, F. Carbonnel, M. Chamailard, L. Zitvogel, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science* **350**, 1079–1084 (2015).
10. V. Gopalakrishnan, C. N. Spencer, L. Nezi, A. Reuben, M. C. Andrews, T. V. Karpinet, P. A. Prieto, D. Vicente, K. Hoffman, S. C. Wei, A. P. Cogdill, L. Zhao, C. W. Hudgens, D. S. Hutchinson, T. Manzo, M. P. de Macedo, T. Cotechini, T. Kumar, W. S. Chen, S. M. Reddy, R. S. Sloane, J. Galloway-Pena, H. Jiang, P. L. Chen, E. J. Shpall, K. Rezvani, A. M. Alousi, R. H. Chermal, S. Shelburne, L. M. Vence, P. C. Okhuysen, V.-L. Jensen, A. G. Swennes, F. McAllister, E. M. R. Sanchez, Y. Zhang, E. Le Chatelier, L. Zitvogel, N. Pons, J. L. Austin-Breneman, L. E. Haydu, E. M. Burton, J. M. Gardner, E. Sirmans, J. Hu, A. J. Lazar, T. Tsujikawa, A. Diab, H. Tawbi, I. C. Glitza, W. J. Hwu, S. P. Patel, S. E. Woodman, R. N. Amaria, M. A. Davies, J. E. Gershenwald, P. Hwu, J. E. Lee, J. Zhang, L. M. Coussens, Z. A. Cooper, P. A. Futreal, C. R. Daniel, N. J. Ajami, J. F. Petrosino, M. T. Tetzlaff, P. Sharma, J. P. Allison, R. R. Jenq, J. A. Wargo, Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science* **359**, 97–103 (2018).
11. V. Matson, J. Fessler, R. Bao, T. Chongsuwan, Y. Zha, M.-L. Alegre, J. J. Luke, T. F. Gajewski, The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science* **359**, 104–108 (2018).
12. K. Dubin, M. K. Callahan, B. Ren, R. Khanin, A. Viale, L. Ling, D. No, A. Gobourne, E. Littmann, C. Huttenhower, E. G. Pamer, J. D. Wolchok, Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. *Nat. Commun.* **7**, 10391 (2016).
13. D. Davar, A. K. Dzutsev, J. A. McCulloch, R. R. Rodrigues, J. M. Chauvin, R. M. Morrison, R. N. Deblasio, C. Menna, Q. Ding, O. Pagliano, B. Zidi, S. Zhang, J. H. Badger, M. Vézizou, A. M. Cole, M. R. Fernandes, S. Prescott, R. G. F. Costa, A. K. Balaji, A. Morgun, I. Vujkovic-Cvijin, H. Wang, A. A. Borhani, M. B. Schwartz, H. M. Dubner, S. J. Ernst, A. Rose, Y. G. Najjar, Y. Belkaid, J. M. Kirkwood, G. Trinchieri, H. M. Zarour, Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. *Science* **371**, 595–602 (2021).
14. E. N. Baruch, I. Youngster, G. Ben-Betzalel, R. Ortenberg, A. Lahat, L. Katz, K. Adler, D. Dick-Necula, S. Raskin, N. Bloch, D. Rotin, L. Anafi, C. Avivi, J. Melnichenko, Y. Steinberg-Silman, R. Mamtani, H. Harati, N. Asher, R. Shapira-Frommer, T. Brosh-Nissimov, Y. Eshet, S. Ben-Simon, O. Ziv, M. A. W. Khan, M. Amit, N. J. Ajami, I. Barshack, J. Schachter, J. A. Wargo, O. Koren, G. Markel, B. Boursi, Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. *Science* **371**, 602–609 (2021).
15. L. Marthey, C. Mateus, C. Mussini, M. Nachury, S. Nancey, F. Grange, C. Zallot, L. Peyrin-Biroulet, J. F. Rahier, M. B. de Beauregard, L. Mortier, C. Coutzac, E. Soularue, E. Lanoy, N. Kapel, D. Plancharde, N. Chaput, C. Robert, F. Carbonnel, Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. *J. Crohns Colitis* **10**, 395–401 (2016).
16. A. Gupta, K. M. De Felice, E. V. Loftus Jr., S. Khanna, Systematic review: Colitis associated with anti-CTLA-4 therapy. *Aliment. Pharmacol. Ther.* **42**, 406–417 (2015).
17. J. R. Brahmer, D. M. Pardoll, Immune checkpoint inhibitors: Making immunotherapy a reality for the treatment of lung cancer. *Cancer Immunol. Res.* **1**, 85–91 (2013).
18. A. S. Thomas, W. Ma, Y. Wang, Ustekinumab for refractory colitis associated with immune checkpoint inhibitors. *N. Engl. J. Med.* **384**, 581–583 (2021).
19. C. R. Stroud, A. Hegde, C. Cherry, A. R. Naqash, N. Sharma, S. Addepalli, S. Cherukuri, T. Parent, J. Hardin, P. Walker, Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. *J. Oncol. Pharm. Pract.* **25**, 551–557 (2019).
20. S. Bishu, J. Melia, W. Sharfman, C. D. Lao, L. A. Fecher, P. D. R. Higgins, Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis. *Gastroenterology* **160**, 932–934.e3 (2021).
21. F. Zou, H. Abu-Sbeih, W. Ma, Y. Peng, W. Qiao, J. Wang, A. Y. Shah, I. C. G. Oliva, S. A. Pihapaul, J. A. Thompson, H. C. Zhang, A. S. Thomas, Y. Wang, Association of chronic immune-mediated diarrhea and colitis with favorable cancer response. *J. Natl. Compr. Canc. Netw.* **19**, 700–708 (2020).
22. N. Iida, A. Dzutsev, C. A. Stewart, L. Smith, N. Bouladoux, R. A. Weingarten, D. A. Molina, R. Salcedo, T. Back, S. Cramer, R.-M. Dai, H. Kiu, M. Cardone, S. Naik, A. K. Patri, E. Wang, F. M. Marincola, K. M. Frank, Y. Belkaid, G. Trinchieri, R. S. Goldszmid, Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. *Science* **342**, 967–970 (2013).
23. F. Sommer, F. Bäckhed, The gut microbiota—Masters of host development and physiology. *Nat. Rev. Microbiol.* **11**, 227–238 (2013).
24. H. Raskov, J. Burchard, H.-C. Pommergaard, Linking gut microbiota to colorectal cancer. *J. Cancer* **8**, 3378–3395 (2017).
25. S. Roy, G. Trinchieri, Microbiota: A key orchestrator of cancer therapy. *Nat. Rev. Cancer* **17**, 271–285 (2017).
26. M. Yi, S. Yu, S. Qin, Q. Liu, H. Xu, W. Zhao, Q. Chu, K. Wu, Gut microbiome modulates efficacy of immune checkpoint inhibitors. *J. Hematol. Oncol.* **11**, 47 (2018).
27. C. N. Spencer, J. L. McQuade, V. Gopalakrishnan, J. A. McCulloch, M. Vézizou, A. P. Cogdill, M. A. W. Khan, X. Zhang, M. G. White, C. B. Peterson, M. C. Wong, G. Morad, T. Rodgers, J. H. Badger, B. A. Helmink, M. C. Andrews, R. R. Rodrigues, A. Morgun, Y. S. Kim, J. Roszik, K. L. Hoffman, J. Zheng, Y. Zhou, Y. B. Medik, L. M. Kahn, S. Johnson, C. W. Hudgens, K. Wani, P. O. Gaudreau, A. L. Harris, M. A. Jamal, E. N. Baruch, E. Perez-Guillermo, C. P. Day, G. Merlino, B. Pazdrak, B. S. Lochmann, R. A. Szczepaniak-Sloane, R. Arora, J. Anderson, C. M. Zobniw, E. Posada, E. Sirmans, J. Simon, L. E. Haydu, E. M. Burton, L. Wang, M. Dang, K. Clise-Dwyer, S. Schneider, T. Chapman, N. A. A. S. Anang, S. Duncan, J. Toker, J. C. Malke, I. C. Glitza, R. N. Amaria, H. A. Tawbi, A. Diab, M. K. Wong, S. P. Patel, S. E. Woodman, M. A. Davies, M. I. Ross, J. E. Gershenwald, J. E. Lee, P. Hwu, V. Jensen, Y. Samuels, R. Straussman, N. J. Ajami, K. C. Nelson, L. Nezi, J. F. Petrosino, P. A. Futreal, A. J. Lazar, J. Hu, R. R. Jenq, M. T. Tetzlaff, Y. Yan, W. S. Garrett, C. Huttenhower, P. Sharma, S. S. Watowich, J. P. Allison, L. Cohen, G. Trinchieri, C. R. Daniel, J. A. Wargo, Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. *Science* **374**, 1632–1640 (2021).
28. N. Dizman, L. Meza, P. Bergerot, M. Alcantara, T. Dorff, Y. Lyou, P. Frankel, Y. Cui, V. Mira, M. Llamas, J. Hsu, Z. Zengin, N. Sargia, S. Sargia, J. Malhotra, N. Chawla, A. Chehrizi-Raffle, R. Muddasani, J. Gillece, L. Reining, J. Trent, M. Takahashi, K. Oka, S. Higashi, M. Kortylewski, S. K. Highlander, S. K. Pal, Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: A randomized phase 1 trial. *Nat. Med.* **28**, 704–712 (2022).
29. N. Chaput, P. Lepage, C. Coutzac, E. Soularue, K. Le Roux, C. Monot, L. Boselli, E. Routier, L. Cassard, M. Collins, T. Vaysse, L. Marthey, A. Eggermont, V. Asvatourian, E. Lanoy, C. Mateus, C. Robert, F. Carbonnel, Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. *Ann. Oncol.* **28**, 1368–1379 (2017).
30. F. Wang, Q. Yin, L. Chen, M. M. Davis, Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. *Proc. Natl. Acad. Sci. U.S.A.* **115**, 157–161 (2018).
31. Y. A. Ghouri, V. Tahan, B. Shen, Secondary causes of inflammatory bowel diseases. *World J. Gastroenterol.* **26**, 3998–4017 (2020).
32. P. J. Basso, M. T. C. Fonseca, G. Bonfá, V. B. F. Alves, H. Sales-Campos, V. Nardini, C. R. B. Cardoso, Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease. *Braz. J. Med. Biol. Res.* **47**, 727–737 (2014).
33. D. Knights, K. G. Lassen, R. J. Xavier, Advances in inflammatory bowel disease pathogenesis: Linking host genetics and the microbiome. *Gut* **62**, 1505–1510 (2013).
34. D. Knights, M. S. Silverberg, R. K. Weersma, D. Gevers, G. Dijkstra, H. Huang, A. D. Tyler, S. van Sommeren, F. Imhann, J. M. Stempak, H. Huang, P. Vangay, G. A. Al-Ghalith, C. Russell, J. Sauk, J. Knight, M. J. Daly, C. Huttenhower, R. J. Xavier, Complex host genetics influence the microbiome in inflammatory bowel disease. *Genome Med.* **6**, 107 (2014).

35. E. A. Barka, P. Vatsa, L. Sanchez, N. Gaveau-Vaillant, C. Jacquard, H.-P. Klenk, C. Clément, Y. Ouhdouch, G. P. van Wezel, Taxonomy, physiology, and natural products of Actinobacteria. *Microbiol. Mol. Biol. Rev.* **80**, 1–43 (2016).
36. A. Rivière, M. Selak, D. Lantin, F. Leroy, L. De Vuyst, Bifidobacteria and butyrate-producing colon bacteria: Importance and strategies for their stimulation in the human gut. *Front. Microbiol.* **7**, 979 (2016).
37. A. O'Callaghan, D. van Sinderen, Bifidobacteria and their role as members of the human gut microbiota. *Front. Microbiol.* **7**, 925 (2016).
38. S.-H. Lee, S.-Y. Cho, Y. Yoon, C. Park, J. Sohn, J.-J. Jeong, B.-N. Jeon, M. Jang, C. An, S. Lee, Y. Y. Kim, G. Kim, S. Kim, Y. Kim, G. Bin Lee, E. J. Lee, S. G. Kim, H. S. Kim, Y. Kim, H. Kim, H.-S. Yang, S. Kim, S. Kim, H. Chung, M. H. Moon, M. H. Nam, J. Y. Kwon, S. Won, J.-S. Park, G. M. Weinstock, C. Lee, K. W. Yoon, H. Park, Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. *Nat. Microbiol.* **6**, 277–288 (2021).
39. S. Sun, L. Luo, W. Liang, Q. Yin, J. Guo, A. M. Rush, Z. Lv, Q. Liang, M. A. Fischbach, J. L. Sonnenburg, D. Dodd, M. M. Davis, F. Wang, Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 27509–27515 (2020).
40. D. Schierová, J. Březina, J. Mrázek, K. O. Fliegerová, S. Kvasnová, L. Bajer, P. Drastich, Gut microbiome changes in patients with active left-sided ulcerative colitis after fecal microbiome transplantation and topical 5-aminosalicylic acid therapy. *Cell* **9**, 2238 (2020).
41. M. T. Alam, G. C. A. Amos, A. R. J. Murphy, S. Murch, E. M. H. Wellington, R. P. Arasaradnam, Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. *Gut Pathog.* **12**, 1 (2020).
42. J. Chen, K. Wright, J. M. Davis, P. Jeraldo, E. V. Marietta, J. Murray, H. Nelson, E. L. Matteson, V. Taneja, An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. *Genome Med.* **8**, 43 (2016).
43. D. Zheng, T. Liwinski, E. Elinav, Interaction between microbiota and immunity in health and disease. *Cell Res.* **30**, 492–506 (2020).
44. H. Nagao-Kitamoto, N. Kamada, Host-microbial cross-talk in inflammatory bowel disease. *Immune Netw.* **17**, 1–12 (2017).
45. M. Joossens, G. Huys, M. Cnockaert, V. De Preter, K. Verbeke, P. Rutgeerts, P. Vandamme, S. Vermeire, Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut* **60**, 631–637 (2011).
46. M. Olaisen, A. Flatberg, A. van Beelen, E. S. R. Granlund, T. C. Martinsen, A. K. Sandvik, R. Fossmark, Bacterial mucosa-associated microbiome in inflamed and proximal non-inflamed ileum of patients with Crohn's disease. *Inflamm. Bowel Dis.* **27**, 12–24 (2021).
47. C. R. Webb, I. Koboziev, K. L. Furr, M. B. Grisham, Protective and pro-inflammatory roles of intestinal bacteria. *Pathophysiology* **23**, 67–80 (2016).
48. C. B. Zhou, Y. L. Zhou, J. Y. Fang, Gut microbiota in cancer immune response and immunotherapy. *Trends Cancer* **7**, 647–660 (2021).
49. Q. Zhao, C. O. Elson, Adaptive immune education by gut microbiota antigens. *Immunology* **154**, 28–37 (2018).
50. G. Fitzgibbon, K. H. G. Mills, The microbiota and immune-mediated diseases: Opportunities for therapeutic intervention. *Eur. J. Immunol.* **50**, 326–337 (2020).
51. Y. Zhou, Y. B. Medik, B. Patel, D. B. Zamlar, S. Chen, T. Chapman, S. Schneider, E. M. Park, R. L. Babcock, T. T. Chrisikos, L. M. Kahn, A. M. Dyevoich, J. E. Pineda, M. C. Wong, A. K. Mishra, S. H. Cass, A. P. Cogdill, D. H. Johnson, S. B. Johnson, K. Wani, D. A. Ledesma, C. W. Hudgens, J. Wang, M. A. Wadud Khan, C. B. Peterson, A. Y. Joon, W. Peng, H. S. Li, R. Arora, X. Tang, M. G. Raso, X. Zhang, W. C. Foo, M. T. Tetzlaff, G. E. Diehl, K. Clise-Dwyer, E. M. Whitley, M. M. Gubin, J. P. Allison, P. Hwu, N. J. Ajami, A. Diab, J. A. Wargo, S. S. Watowich, Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. *J. Exp. Med.* **220**, e20221333 (2023).
52. Y. Hailemichael, D. H. Johnson, N. Abdel-Wahab, W. C. Foo, S.-E. Benteibibel, M. Daher, C. Haymaker, K. Wani, C. Saberian, D. Ogata, S. T. Kim, R. Nurieva, A. J. Lazar, H. Abu-Sbeih, F. Fa'ak, A. Mathew, Y. Wang, A. Falohun, V. Trinh, C. Zobiw, C. Spillson, J. K. Burks, M. Awiwi, K. Elsayes, L. S. Soto, B. D. Melendez, M. A. Davies, J. Wargo, J. Curry, C. Yee, G. Lizee, S. Singh, P. Sharma, J. P. Allison, P. Hwu, S. Ekmekcioglu, A. Diab, Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. *Cancer Cell* **40**, 509–523.e6 (2022).
53. A. Prodan, V. Tremaroli, H. Brolin, A. H. Zwinderman, M. Nieuwdorp, E. Levin, Comparing bioinformatic pipelines for microbial 16S rRNA amplicon sequencing. *PLOS ONE* **15**, e0227434 (2020).
54. T. Rognes, T. Flouri, B. Nichols, C. Quince, F. Mahé, VSEARCH: A versatile open source tool for metagenomics. *PeerJ* **4**, e2584 (2016).
55. R. Edgar, UNOISE2: Improved error-correction for Illumina 16S and ITS amplicon sequencing. bioRxiv 081257 [Preprint]. 15 October 2016. <https://doi.org/10.1101/081257>.
56. P. D. Schloss, S. L. Westcott, T. Ryabin, J. R. Hall, M. Hartmann, E. B. Hollister, R. A. Lesniewski, B. B. Oakley, D. H. Parks, C. J. Robinson, J. W. Sahl, B. Stres, G. G. Thallinger, D. J. Van Horn, C. F. Weber, Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl. Environ. Microbiol.* **75**, 7537–7541 (2009).
57. E. Pruesse, C. Quast, K. Knittell, B. M. Fuchs, W. Ludwig, J. Peplies, F. O. Glöckner, SILVA: A comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. *Nucleic Acids Res.* **35**, 7188–7196 (2007).
58. C. A. Lozupone, M. Hamady, S. T. Kelley, R. Knight, Quantitative and qualitative beta diversity measures lead to different insights into factors that structure microbial communities. *Appl. Environ. Microbiol.* **73**, 1576–1585 (2007).
59. F. Beghini, L. J. McIver, A. Blanco-Míguez, L. Dubois, F. Asnicar, S. Maharjan, A. Mailyan, P. Manghi, M. Scholz, A. M. Thomas, M. Valles-Colomer, G. Weingart, Y. Zhang, M. Zolfo, C. Huttenhower, E. A. Franzosa, N. Segata, Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with biobakery 3. *eLife* **10**, e65088 (2021).
60. Y. W. Yang, M. K. Chen, B. Y. Yang, X. J. Huang, X. R. Zhang, L. Q. He, J. Zhang, Z. C. Hua, Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in mouse feces. *Appl. Environ. Microbiol.* **81**, 6749–6756 (2015).
61. T. Matsuki, K. Watanabe, R. Tanaka, Genus- and species-specific PCR primers for the detection and identification of bifidobacteria. *Curr. Issues Intest. Microbiol.* **4**, 61–69 (2003).
62. A. Kageyama, M. Sakamoto, Y. Benno, Rapid identification and quantification of Collinsella aerofaciens using PCR. *FEMS Microbiol. Lett.* **183**, 43–47 (2000).
63. E. R. Parra, M. C. Ferrufino-Schmidt, A. Tamegnon, J. Zhang, L. Solis, M. Jiang, H. Ibarguen, C. Haymaker, J. J. Lee, C. Bernatchez, I. I. Wistuba, Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. *Sci. Rep.* **11**, 8511 (2021).
64. C. Laberiano-Fernández, S. Hernández-Ruiz, F. Rojas, E. R. Parra, Best practices for technical reproducibility assessment of multiplex immunofluorescence. *Front. Mol. Biosci.* **8**, 660202 (2021).
65. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
66. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J. R. Stat. Soc. Series B Stat. Methodol.* **57**, 289–300 (1995).

**Acknowledgments:** This study was supported by the Translational Molecular Pathology-Immunoprofiling Moonshots Platform (TMP-IL) at the Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center. We thank the members of the Multiplex Immunofluorescence and Image Analysis Laboratory, part of the TMP-IL platform, who contribute daily to quality staining, analysis, and interpretation of data from multiplexed image technologies. In addition, we thank B. Sanchez-Espiridon and S. Wijeratne for assistance with project management, sample procurement, and inventory, as well as M. Jiang, A. Tamegnon, H. Ibarguen, and R. K. Pandurengan for technical assistance. In addition, T.M.H.'s time was supported by a predoctoral fellowship from Cancer Prevention Research Institute of Texas grant #RP210042. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. **Funding:** We are grateful for the following funding support: Andrew Sabin Family Fellows Program (private donation to Y.W.), HESI Thrive foundation (600700-90-100300-54-MDGRN-00011143-1111 to Y.W.), Moonshot (710499-80-122165-21 to Y.W.), National Institutes of Health (R01 HL124112 to R.R.J.), Cancer Prevention and Research Institute of Texas Grant (RR160089 to R.R.J.), and Cancer Center Support (CORE) Grant (5P30CA016672-42 to R.R.J.). **Author contributions:** Y.W. recruited and treated patients and collected stool samples. A.S.T., W.M., and H.A.-S. contributed to clinical data collection and analysis. Z.-D.J. and H.L.D. contributed to donor's stool and manuscript review and revision. T.M.H., T.H., C.S., R.E.-H., A.B., I.F., L.M., M.H., M.O.T., D.P., S.S.W., E.H., C.-C.C., and R.R.J. completed stool studies and analyzed/interpreted data. B.S. and E.R.P. completed multiplex IF studies and analyzed/interpreted data. T.M.H., A.S.T., R.R.J., and Y.W. prepared the manuscript. All authors approved the manuscript. **Competing interests:** Y.W. has consulted for AzurRx BioPharma, Tillotts Pharma, and Sanarentero. R.R.J. is on the scientific advisory board for Seres Therapeutics Inc., has consulted for Ziopharm Oncology and Microbiome Dx, and holds patents licensed to Seres Therapeutics Inc. The other authors declare that they have no competing interests. **Data and materials availability:** All data associated with this study are present in the paper or the Supplementary Materials. Human 16S rRNA and whole DNA shotgun sequencing data have been uploaded to the Sequence Read Archive (SRA) under citation accession PRJNA803517. This research was funded in whole or in part by the Cancer Moonshot program. The authors will make the Author Accepted Manuscript (AAM) version available under a CC BY public copyright license.

Submitted 5 April 2022  
Accepted 19 May 2023  
Published 14 June 2023  
10.1126/scitranslmed.abq4006

## Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor–induced colitis

Taylor M. Halsey, Anusha S. Thomas, Tomo Hayase, Weijie Ma, Hamzah Abu-Sbeih, Baohua Sun, Edwin Roger Parra, Zhi-Dong Jiang, Herbert L. DuPont, Christopher Sanchez, Rawan El-Himri, Alexandria Brown, Ivonne Flores, Lauren McDaniel, Miriam Ortega Turrubiates, Matthew Hensel, Dung Pham, Stephanie S. Watowich, Eiko Hayase, Chia-Chi Chang, Robert R. Jenq, and Yinghong Wang

*Sci. Transl. Med.*, **15** (700), eabq4006.  
DOI: 10.1126/scitranslmed.abq4006

### View the article online

<https://www.science.org/doi/10.1126/scitranslmed.abq4006>

### Permissions

<https://www.science.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of service](#)

---

*Science Translational Medicine* (ISSN ) is published by the American Association for the Advancement of Science. 1200 New York Avenue NW, Washington, DC 20005. The title *Science Translational Medicine* is a registered trademark of AAAS.  
Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works